Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVMNASDAQ:BLUENASDAQ:CLLSNASDAQ:EDIT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$3.33+2.1%$4.00$2.64▼$10.84$69.57M1.1266,223 shs555,523 shsBLUEbluebird bio$4.05-0.7%$4.23$3.56▼$28.60$39.65M0.41371,850 shs67,230 shsCLLSCellectis$1.61-1.9%$1.34$1.10▼$3.38$89.66M3.22145,573 shs78,184 shsEDITEditas Medicine$1.62-1.8%$1.42$0.91▼$6.69$135.61M2.162.58 million shs1.09 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies+2.15%+12.12%-13.05%-21.09%-65.99%BLUEbluebird bio-0.74%-2.64%-22.86%-47.74%-77.73%CLLSCellectis-1.95%+6.82%+22.20%+0.19%-36.40%EDITEditas Medicine-1.82%+0.62%+43.36%+23.66%-70.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0104 of 5 stars3.42.00.04.81.92.50.6BLUEbluebird bio2.9983 of 5 stars3.14.00.00.02.22.51.3CLLSCellectis3.132 of 5 stars3.55.00.00.03.22.50.0EDITEditas Medicine4.1565 of 5 stars3.23.00.04.22.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.80Moderate Buy$26.60698.80% UpsideBLUEbluebird bio 2.25Hold$44.601,001.23% UpsideCLLSCellectis 3.00Buy$7.00333.97% UpsideEDITEditas Medicine 2.31Hold$6.54303.61% UpsideCurrent Analyst Ratings BreakdownLatest EDIT, ADVM, CLLS, and BLUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.004/17/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $33.004/16/2025ADVMAdverum BiotechnologiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$10.00 ➝ $5.004/16/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/31/2025BLUEbluebird bioBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $8.002/24/2025BLUEbluebird bioWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$40.00 ➝ $5.002/24/2025BLUEbluebird bioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral2/21/2025BLUEbluebird bioBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M69.57N/AN/A$8.26 per share0.40BLUEbluebird bio$83.81M0.47N/AN/A$35.59 per share0.11CLLSCellectis$41.51M2.16N/AN/A$1.52 per share1.06EDITEditas Medicine$32.31M4.20N/AN/A$4.27 per share0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$5.65N/AN/AN/AN/A-65.14%-40.52%5/8/2025 (Estimated)BLUEbluebird bio-$211.91M-$45.54N/AN/AN/A-565.74%-322.46%-53.17%5/7/2025 (Estimated)CLLSCellectis-$101.06M-$0.83N/AN/AN/A-234.39%-74.55%-22.65%5/5/2025 (Estimated)EDITEditas Medicine-$153.22M-$2.88N/AN/AN/A-340.96%-80.13%-50.99%5/6/2025 (Estimated)Latest EDIT, ADVM, CLLS, and BLUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025EDITEditas Medicine-$0.52N/AN/AN/A$0.79 millionN/A5/8/2025Q4 2024ADVMAdverum Biotechnologies-$1.34N/AN/AN/AN/AN/A5/7/2025Q1 2025BLUEbluebird bio-$2.42N/AN/AN/A$39.03 millionN/A4/15/2025Q4 2024ADVMAdverum Biotechnologies-$1.34-$1.96-$0.62-$1.96N/AN/A3/13/2025Q4 2024CLLSCellectis$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 million3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ABLUEbluebird bioN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A5.825.82BLUEbluebird bio0.370.510.33CLLSCellectis0.481.781.78EDITEditas MedicineN/A3.753.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%BLUEbluebird bio87.43%CLLSCellectis63.90%EDITEditas Medicine71.90%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies4.20%BLUEbluebird bio1.40%CLLSCellectis16.41%EDITEditas Medicine1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.89 million19.93 millionOptionableBLUEbluebird bio5209.79 million9.59 millionOptionableCLLSCellectis29055.58 million46.46 millionOptionableEDITEditas Medicine23083.71 million80.98 millionOptionableEDIT, ADVM, CLLS, and BLUE HeadlinesRecent News About These CompaniesHC Wainwright Estimates Editas Medicine Q1 EarningsMay 2 at 1:22 AM | americanbankingnews.comHC Wainwright Upgrades Editas Medicine (NASDAQ:EDIT) to Strong-BuyMay 1 at 6:46 AM | marketbeat.comEditas Medicine (NASDAQ:EDIT) Upgraded by HC Wainwright to Strong-Buy RatingMay 1 at 3:41 AM | americanbankingnews.comAnalysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $6.83May 1 at 2:23 AM | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from AnalystsApril 30 at 8:42 AM | marketbeat.comGlobal CRISPR and Cas Gene Market Poised for Explosive Growth, Expected to Reach USD 56,087 Million by 2035April 29 at 10:38 PM | fmiblog.comEditas Medicine to Present Preclinical Data De [...]April 29 at 12:36 PM | aktiencheck.deHC Wainwright & Co. Initiates Coverage of Editas Medicine (EDIT) with Buy RecommendationApril 29 at 12:36 PM | msn.comEditas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual MeetingApril 28, 2025 | globenewswire.comRenaissance Technologies LLC Acquires Shares of 1,451,049 Editas Medicine, Inc. (NASDAQ:EDIT)April 28, 2025 | marketbeat.comEditas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past yearApril 23, 2025 | finance.yahoo.comToolGen files patent infringement lawsuit against Vertex Pharma in UK for genome editing therapy CASGEVYApril 22, 2025 | pharmabiz.comToolGen Files Patent Infringement Lawsuit Against Vertex in the United KingdomApril 21, 2025 | informazione.itLeerink Partnrs Predicts Editas Medicine Q3 EarningsApril 20, 2025 | marketbeat.comLeerink Partnrs Forecasts Editas Medicine Q1 EarningsApril 19, 2025 | marketbeat.comCity Therapeutics Expands Executive Team and Board of DirectorsApril 17, 2025 | finance.yahoo.comWhy Editas Medicine, Inc.’s (EDIT) Stock Is Down 5.16%April 17, 2025 | aaii.comGC Therapeutics Expands Leadership Team with Industry Veterans Kai-Hsin Chang and Azadeh GolipourApril 15, 2025 | finance.yahoo.com238,967 Shares in Editas Medicine, Inc. (NASDAQ:EDIT) Bought by Raymond James Financial Inc.April 12, 2025 | marketbeat.comBroad, Harvard researchers win Breakthrough Prize, known as 'Oscars of Science'April 6, 2025 | bizjournals.comWhy Is Editas (EDIT) Down 37.1% Since Last Earnings Report?April 4, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatCellectis Charts Course for 2025 With Boost From AstraZeneca DealBy Jeffrey Neal Johnson | April 22, 2025View Cellectis Charts Course for 2025 With Boost From AstraZeneca DealEDIT, ADVM, CLLS, and BLUE Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$3.33 +0.07 (+2.15%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$3.33 0.00 (0.00%) As of 05/1/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.bluebird bio NASDAQ:BLUE$4.05 -0.03 (-0.74%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$4.14 +0.09 (+2.35%) As of 05/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Cellectis NASDAQ:CLLS$1.62 -0.03 (-1.82%) As of 05/1/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Editas Medicine NASDAQ:EDIT$1.62 -0.03 (-1.82%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$1.62 -0.01 (-0.31%) As of 05/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
